Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDBridgeBio Oncology Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 4 | -$0.52 | -$0.50 | -$0.51 |
| Q2 2026 | 5 | -$0.62 | -$0.50 | -$0.56 |
| Q3 2026 | 5 | -$0.63 | -$0.52 | -$0.58 |
| Q4 2026 | 1 | -$0.57 | -$0.57 | -$0.57 |
| Q1 2027 | 1 | -$0.54 | -$0.54 | -$0.54 |
| Q2 2027 | 1 | -$0.54 | -$0.54 | -$0.54 |
| Q3 2027 | 1 | -$0.55 | -$0.55 | -$0.55 |
| Q4 2027 | 1 | -$0.55 | -$0.55 | -$0.55 |
| Q1 2028 | 2 | -$0.39 | -$0.39 | -$0.39 |
| Q2 2028 | 2 | -$0.39 | -$0.39 | -$0.39 |
| Q3 2028 | 2 | -$0.40 | -$0.40 | -$0.40 |
| Q4 2028 | 2 | -$0.40 | -$0.40 | -$0.40 |
BridgeBio Oncology Therapeutics Inc. Earnings Date And Information
BridgeBio Oncology Therapeutics Inc. last posted its earnings results on Thursday, June 4th, 2026. The company reported $-0.52611 earnings per share for the quarter, missing analysts' consensus estimates of $-0.51197 by $0.01414. The company had revenue of 0 for the quarter and had revenue of 0 for the year. BridgeBio Oncology Therapeutics Inc. has generated $-4 earnings per share over the last year ($-4.3 diluted earnings per share) and currently has a price-to-earnings ratio of -1.3. BridgeBio Oncology Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
BridgeBio Oncology Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/12/2026 | Q1 2026 | -$0.51 | -$1.35 | -0.84 | $0 | $0 |
| 03/05/2026 | Q4 2025 | N/A | -$1.25 | N/A | $0 | $0 |
| 11/12/2025 | Q3 2025 | -$0.41 | -$1.90 | -1.49 | $0 | $0 |
| 08/01/2025 | Q2 2025 | N/A | -$1.21 | N/A | $0 | $0 |
| 05/15/2025 | Q1 2025 | N/A | -$0.94 | N/A | N/A | $0 |
| 03/10/2025 | Q4 2024 | N/A | $0.12 | N/A | N/A | $0 |
| 11/14/2024 | Q3 2024 | N/A | -$0.74 | N/A | N/A | $0 |
| 08/14/2024 | Q2 2024 | N/A | $0.09 | N/A | N/A | $0 |
| 05/15/2024 | Q1 2024 | N/A | $0.05 | N/A | N/A | $0 |
| 12/30/2023 | Q4 2023 | N/A | -$0.00 | N/A | N/A | $0 |
| 12/30/2022 | Q4 2022 | N/A | -$0.00 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
BridgeBio Oncology Therapeutics Inc. Earnings: FAQ's
The conference call for BridgeBio Oncology Therapeutics Inc.'s latest earnings report can be listened to online.
The conference call transcript for BridgeBio Oncology Therapeutics Inc.'s latest earnings report can be read online.
BridgeBio Oncology Therapeutics Inc. (:BBOT) has a recorded net income of $-134,044,000.BridgeBio Oncology Therapeutics Inc. has generated $-4.3 earnings per share over the last four quarters.
BridgeBio Oncology Therapeutics Inc. (:BBOT) has a price-to-earnings ratio of -1.3 and price/earnings-to-growth ratio is 0.01.